Login to Your Account

Genmab to Outlicense Antibody Following ASH Data Release

By Nuala Moran
BioWorld International Correspondent

Wednesday, December 28, 2011

LONDON – Genmab A/S is close to outlicensing its second major antibody program – daratumumab – after presenting positive Phase I/II results and said it is determined to avoid the pitfalls that have to date muted the success of its first product, ofatumumab (Arzerra).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription